Interactions

See also

References

Further reading

• Petrova TV, Makinen T, Alitalo K (November 1999). "Signaling via vascular endothelial growth factor receptors".Experimental Cell Research.253 (1):117–30.doi:10.1006/excr.1999.4707.PMID 10579917.
• Aprelikova O, Pajusola K, Partanen J, Armstrong E, Alitalo R, Bailey SK, McMahon J, Wasmuth J, Huebner K, Alitalo K (February 1992). "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter".Cancer Research.52 (3):746–8.PMID 1310071.
• Galland F, Karamysheva A, Mattei MG, Rosnet O, Marchetto S, Birnbaum D (June 1992). "Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene".Genomics.13 (2):475–8.doi:10.1016/0888-7543(92)90277-Y.PMID 1319394.
• Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R, Alitalo K (October 1992). "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines".Cancer Research.52 (20):5738–43.PMID 1327515.
• Fournier E, Dubreuil P, Birnbaum D, Borg JP (September 1995). "Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor".Oncogene.11 (5):921–31.PMID 7675451.
• Pajusola K, Aprelikova O, Armstrong E, Morris S, Alitalo K (November 1993). "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts".Oncogene.8 (11):2931–7.PMID 7692369.
• Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K (December 1994). "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors".Oncogene.9 (12):3545–55.PMID 7970715.
• Galland F, Karamysheva A, Pebusque MJ, Borg JP, Rottapel R, Dubreuil P, Rosnet O, Birnbaum D (May 1993). "The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor".Oncogene.8 (5):1233–40.PMID 8386825.
• Fournier E, Rosnet O, Marchetto S, Turck CW, Rottapel R, Pelicci PG, Birnbaum D, Borg JP (May 1996)."Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase".The Journal of Biological Chemistry.271 (22):12956–63.doi:10.1074/jbc.271.22.12956.PMID 8662748.
• Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI (March 1996)."Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4".Proceedings of the National Academy of Sciences of the United States of America.93 (5):1988–92.Bibcode:1996PNAS...93.1988L.doi:10.1073/pnas.93.5.1988.PMC 39896.PMID 8700872.
• Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K (December 1996). "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development".Development.122 (12):3829–37.doi:10.1242/dev.122.12.3829.PMID 9012504.
• Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA (January 1998)."Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)".Proceedings of the National Academy of Sciences of the United States of America.95 (2):548–53.Bibcode:1998PNAS...95..548A.doi:10.1073/pnas.95.2.548.PMC 18457.PMID 9435229.
• Ferrell RE, Levinson KL, Esman JH, Kimak MA, Lawrence EC, Barmada MM, Finegold DN (December 1998). "Hereditary lymphedema: evidence for linkage and genetic heterogeneity".Human Molecular Genetics.7 (13):2073–8.doi:10.1093/hmg/7.13.2073.PMID 9817924.
• Fournier E, Blaikie P, Rosnet O, Margolis B, Birnbaum D, Borg JP (January 1999)."Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling".Oncogene.18 (2):507–14.doi:10.1038/sj.onc.1202315.PMID 9927207.
• Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN (June 2000). "Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema".Nature Genetics.25 (2):153–9.doi:10.1038/75997.PMID 10835628.S2CID 38445644.
• Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M (August 2000)."Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase".American Journal of Human Genetics.67 (2):295–301.doi:10.1086/303019.PMC 1287178.PMID 10856194.
• Wang JF, Zhang XF, Groopman JE (November 2001)."Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration".The Journal of Biological Chemistry.276 (45):41950–7.doi:10.1074/jbc.M101370200.PMID 11553610.
• Baldwin ME, Roufail S, Halford MM, Alitalo K, Stacker SA, Achen MG (November 2001)."Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis".The Journal of Biological Chemistry.276 (47):44307–14.doi:10.1074/jbc.M106188200.PMID 11574540.
• Walter JW, North PE, Waner M, Mizeracki A, Blei F, Walker JW, Reinisch JF, Marchuk DA (March 2002). "Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma".Genes, Chromosomes & Cancer.33 (3):295–303.doi:10.1002/gcc.10028.PMID 11807987.S2CID 33428561.

External links